Anticoagulant Reversal Drugs Market By Drug Type (Vitamin K Antagonists, Direct Oral Anticoagulants Reversal, Dabigatran, Rivaroxaban, Apixaban, Heparin Reversal, Others), By Indication (Bleeding Control, Emergency Reversal, Pre-surgical Reversal), By Route of Administration (Oral, Parenteral), By End-User (Hospitals, Ambulatory Surgical Centers, Clinics, Home Care Settings), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035.

Published Date: Dec 2024 | Report ID: MI1548 | 245 Pages

Report Summary Table of Contents Segmentation FAQ Request Free Sample Report

Report Coverage:

By Drug Type

  • Vitamin K Antagonists
  • Direct Oral Anticoagulants Reversal
  • Dabigatran
  • Rivaroxaban
  • Apixaban
  • Heparin Reversal
  • Others

By Indication

  • Bleeding Control
  • Emergency Reversal
  • Pre-surgical Reversal

By Route of Administration

  • Oral
  • Parenteral

By End-User

  • Hospitals
  • Ambulatory Surgical Centers
  • Clinics
  • Home Care Settings

By Region

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • France
  • Germany
  • Italy
  • Spain
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Singapore
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

List of Companies:

  • Bayer AG
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Pfizer Inc.
  • Baxter International
  • Amgen Inc.
  • Sanofi S.A.
  • Roche Holding AG
  • Portola Pharmaceuticals
  • Grifols
  • Novo Nordisk
  • AstraZeneca
  • Hematologic Technologies Inc.
  • Idorsia Pharmaceuticals
  • Regeneron Pharmaceuticals
  • Johnson & Johnson
  • Exelixis Inc.
  • Eli Lilly and Company

Maximize your value and knowledge with our 5 Reports-in-1 Bundle - over 40% off!

Our analysts are ready to help you immediately.

Request Bundle Pricing